Блог – PharmCAT.NET

PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 6, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Piasky, Crovalimab, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Date of authorisation: 22/11/2018, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Pemetrexed Pfizer (previously Pemetrexed Hospira), pemetrexed, Date of authorisation: 19/11/2015, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Date of authorisation: 14/02/2025, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 15, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): RotaTeq, rotavirus vaccine, live, Date of authorisation: 26/06/2006, Revision: 38, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Summary of opinion: Amvuttra, 25/04/2025 Positive
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-04-25
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion
Source: EMA - New medicines: human Published on 2025-04-25
Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion
Source: EMA - New medicines: human Published on 2025-04-25
Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion
Source: EMA - New medicines: human Published on 2025-04-25
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion
Source: EMA - New medicines: human Published on 2025-04-25
Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion
Source: EMA - New medicines: human Published on 2025-04-25

Предыдущие записи

Тема: Scaffold от Danny Cooper.